Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Sparsentan (SPAR) is a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), approved in the US and Europe for adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Approval was based on the PROTECT trial (NCT03762850) that found greater reductions in proteinuria and superior preservation of kidney function over 2 years with SPAR vs maximum labeled dose irbesartan (IRB). An interim analysis of the phase 2, single-arm, open-label SPARTAN trial (NCT04663204) offered insights into the potential underlying mechanisms mediating SPAR’s nephroprotective effects, reporting rapid and sustained reductions in urine biomarkers of inflammation and fibrosis, including sCD163 (a marker of macrophage activation), BAFF, and sC5b-9, in 11 incident patients with IgAN treated with SPAR. To further elucidate the mechanisms by which SPAR preserves kidney function, we will present an analysis of these urine biomarkers in PROTECT, allowing an assessment in a larger IgAN population in the setting of a phase 3, randomized, double-blind, active-controlled trial of SPAR vs maximum labeled dose IRB.
PROTECT was a multicenter, parallel-group trial that enrolled 404 patients who were randomized (1:1) to receive SPAR 400 mg/day (n=202) or IRB 300 mg/day (n=202) for up to 110 weeks. Patients were ≥18 years old, had biopsy-proven IgAN, had urine protein excretion ≥1.0 g/day, had estimated glomerular filtration rate ≥30 mL/min/1.73 m2, and were at high risk of progression to kidney failure despite maximized treatment with an angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker. For this analysis, we will report the change from baseline in urine biomarker levels that are measured by ELISA and normalized to creatinine concentration. Biomarker levels will be analyzed using descriptive summary statistics.
We will present baseline characteristics for SPAR and IRB patients included in this analysis. Additionally, we will report change from baseline in urine biomarker excretion for key biomarkers, including sCD163, BAFF, and sC5b-9.
This analysis will evaluate the effect of SPAR vs maximum labeled dose IRB on urine biomarkers of inflammation and fibrosis in patients with IgAN in PROTECT. These analyses will help to clarify SPAR’s mechanism of action beyond hemodynamic actions.
